243 related articles for article (PubMed ID: 18952105)
61. Modelling strategic use of the national antiviral stockpile during the CONTAIN and SUSTAIN phases of an Australian pandemic influenza response.
McVernon J; McCaw JM; Nolan TM
Aust N Z J Public Health; 2010 Apr; 34(2):113-9. PubMed ID: 23331352
[TBL] [Abstract][Full Text] [Related]
62. Intervention strategies for an influenza pandemic taking into account secondary bacterial infections.
Handel A; Longini IM; Antia R
Epidemics; 2009 Sep; 1(3):185-95. PubMed ID: 20161493
[TBL] [Abstract][Full Text] [Related]
63. Population-wide emergence of antiviral resistance during pandemic influenza.
Moghadas SM; Bowman CS; Röst G; Wu J
PLoS One; 2008 Mar; 3(3):e1839. PubMed ID: 18350174
[TBL] [Abstract][Full Text] [Related]
64. Exploring Ugi-Azide Four-Component Reaction Products for Broad-Spectrum Influenza Antivirals with a High Genetic Barrier to Drug Resistance.
Zhang J; Hu Y; Foley C; Wang Y; Musharrafieh R; Xu S; Zhang Y; Ma C; Hulme C; Wang J
Sci Rep; 2018 Mar; 8(1):4653. PubMed ID: 29545578
[TBL] [Abstract][Full Text] [Related]
65. The impact of prophylaxis of healthcare workers on influenza pandemic burden.
Gardam M; Liang D; Moghadas SM; Wu J; Zeng Q; Zhu H
J R Soc Interface; 2007 Aug; 4(15):727-34. PubMed ID: 17360253
[TBL] [Abstract][Full Text] [Related]
66. The timing and targeting of treatment in influenza pandemics influences the emergence of resistance in structured populations.
Althouse BM; Patterson-Lomba O; Goerg GM; Hébert-Dufresne L
PLoS Comput Biol; 2013; 9(2):e1002912. PubMed ID: 23408880
[TBL] [Abstract][Full Text] [Related]
67. Next-Generation Sequencing: An Eye-Opener for the Surveillance of Antiviral Resistance in Influenza.
Van Poelvoorde LAE; Saelens X; Thomas I; Roosens NH
Trends Biotechnol; 2020 Apr; 38(4):360-367. PubMed ID: 31810633
[TBL] [Abstract][Full Text] [Related]
68. Simple models for containment of a pandemic.
Arino J; Brauer F; van den Driessche P; Watmough J; Wu J
J R Soc Interface; 2006 Jun; 3(8):453-7. PubMed ID: 16849273
[TBL] [Abstract][Full Text] [Related]
69. Optimizing treatment regimes to hinder antiviral resistance in influenza across time scales.
Patterson-Lomba O; Althouse BM; Goerg GM; Hébert-Dufresne L
PLoS One; 2013; 8(3):e59529. PubMed ID: 23555694
[TBL] [Abstract][Full Text] [Related]
70. Recent discoveries of influenza A drug target sites to combat virus replication.
Patel H; Kukol A
Biochem Soc Trans; 2016 Jun; 44(3):932-6. PubMed ID: 27284062
[TBL] [Abstract][Full Text] [Related]
71. Can treatment increase the epidemic size?
Xiao Y; Brauer F; Moghadas SM
J Math Biol; 2016 Jan; 72(1-2):343-61. PubMed ID: 25925242
[TBL] [Abstract][Full Text] [Related]
72. A comparative evaluation of modelling strategies for the effect of treatment and host interactions on the spread of drug resistance.
Alexander ME; Dietrich SM; Hua Y; Moghadas SM
J Theor Biol; 2009 Jul; 259(2):253-63. PubMed ID: 19344730
[TBL] [Abstract][Full Text] [Related]
73. Estimation of optimal antiviral stockpile for a novel influenza pandemic.
Kim S; Bin Seo Y; Lee J; Kim YS; Jung E
J Infect Public Health; 2022 Jul; 15(7):720-725. PubMed ID: 35667304
[TBL] [Abstract][Full Text] [Related]
74. Modelling the emergence of influenza drug resistance: The roles of surface proteins, the immune response and antiviral mechanisms.
Dobrovolny HM; Beauchemin CAA
PLoS One; 2017; 12(7):e0180582. PubMed ID: 28700622
[TBL] [Abstract][Full Text] [Related]
75. Combination strategies for pandemic influenza response - a systematic review of mathematical modeling studies.
Lee VJ; Lye DC; Wilder-Smith A
BMC Med; 2009 Dec; 7():76. PubMed ID: 20003249
[TBL] [Abstract][Full Text] [Related]
76. Evolution of Influenza Viruses-Drug Resistance, Treatment Options, and Prospects.
Smyk JM; Szydłowska N; Szulc W; Majewska A
Int J Mol Sci; 2022 Oct; 23(20):. PubMed ID: 36293099
[TBL] [Abstract][Full Text] [Related]
77. How necessary is a fast testkit for mitigation of pandemic flu?
Chin J; Koh G; Lee DY
J R Soc Interface; 2010 Jul; 7(48):1033-47. PubMed ID: 20022897
[TBL] [Abstract][Full Text] [Related]
78. Modelling the outbreak of infectious disease following mutation from a non-transmissible strain.
Chen CY; Ward JP; Xie WB
Theor Popul Biol; 2019 Apr; 126():1-18. PubMed ID: 30165060
[TBL] [Abstract][Full Text] [Related]
79. Antiviral agents for influenza: molecular targets, concerns of resistance, and new treatment options.
Maltezou HC; Tsiodras S
Curr Drug Targets; 2009 Oct; 10(10):1041-8. PubMed ID: 19860646
[TBL] [Abstract][Full Text] [Related]
80. Influenza will not miss opportunities.
Kaiser L
Clin Infect Dis; 2006 Dec; 43(12):1562-4. PubMed ID: 17109289
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
